TICKERNERD
Menu
CMNDCMNDHealthcare · Biotechnology

CMND Stock Forecast: Clearmind Medicine, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$0.80
−6.83% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 6 of 100 as at 19 Sept 2026 — in the weakest quartile.

Market cap
$2.7M
Ticker Nerd rank
6 / 100
Median analyst target
—
Analysts covering
—
Revenue$0.0
Operating income−$2.2M
Net income−$907K
Free cash flow−$2.7M
Quarterly, 8 quarters to 31 July 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−17.3%
1M
−59.2%
YTD
−95.6%
1Y
−99.8%
From 52W high
−99.8%
From 52W low
0.0%
$1
$476
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CMND stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Clearmind Medicine, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
6 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
98
Quality
34
Growth
26
Revisions
25
Accruals
21
Momentum
16
Volatility
16
Issuance
4
Value
3

Size (98): Smaller than most of the companies we track.

Value (3): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CMND stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CMND, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$100$200$300$400Oct 25Jan 26Apr 26Jul 26CMND

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CMND appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CMND vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Clearmind Medicine, Inc. returned −99.8% against +16.3% for the S&P 500, dividends included.

CMND vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Oct 25Jan 26Apr 26Jul 26CMNDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CMND analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Clearmind Medicine, Inc. (CMND) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.2×

Cheaper than 72% of US stocks

Price / sales
—
Price / book
0.0×

Cheaper than 92% of US stocks

EV / EBITDA
1.3×

Cheaper than 57% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−107.0%

Higher than 13% of US stocks

Return on assets
−53.1%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Clearmind Medicine, Inc. (CMND) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Clearmind Medicine, Inc. has a market value of $2.7M and an enterprise value of −$11.4M.

  • Revenue in the twelve months to 31 July 2026: $0.0.

  • Net income over the same four quarters: −$7.5M.

  • Free cash flow in the twelve months to 31 July 2026: −$7.8M.

  • Shares outstanding: 1.5M.

  • Trailing P/E: 0.2×.

  • Clearmind Medicine, Inc. employs 0 people.

Statement figures: company filings via Twelve Data, four quarters to 31 July 2026 · market figures as at 20 Sept 2026

Data provided by Twelve Data

Peers

CMND vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CMNDClearmind Medicine, Inc.$2.7M
6
ONCOOnconetix, Inc.$2.8M
16
GNPXGenprex, Inc.$2.8M
9
SPRCSciSparc Ltd.$2.6M
19
CLDICalidi Biotherapeutics, Inc.$2.8M
23
BCABBioAtla, Inc.$2.9M
—
SILOSilo Pharma, Inc.$2.9M
24

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Clearmind Medicine, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CMND news & analysis

Stickit Technologies Announces Corporate Update: Leadership Appointments, Capital Restructuring & Loan Acquisition, And Update Of Intellectual Property Portfolio

TheNewswire · 17 Sept 2026neutral

StickIt Technologies issued a corporate update outlining changes to its board of directors and executive management, recent financial transactions including loan acquisitions and private placements, and developments across its international intellectual property portfolio of proprietary cannabinoid and plant extract delivery technologies.

Why it matters — As a company developing and patenting cannabinoid and plant extract delivery technologies, StickIt's leadership, financing, and IP developments are relevant context for those tracking competitors in the cannabinoid delivery space relevant to Clearmind Medicine.

Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.

GlobeNewsWire · 17 Sept 2026positive

Clearmind Medicine delivered a briefing to the FDA after being invited to participate in a historic psychedelic hearing in Washington, D.C. Mary-Elizabeth Gifford, Chief of Global Impact, spoke on patient access and shared insights from Clearmind's clinical trial at Yale and Johns Hopkins.

Why it matters — This positions Clearmind as an active participant in high-level FDA and psychedelic policy discussions, potentially raising its profile among regulators and investors.

Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial

GlobeNewsWire · 11 Sept 2026positive

Clearmind Medicine announced that the first patients with Alcohol Use Disorder have been enrolled in its ongoing clinical trial evaluating CMND-100, the company's proprietary psychedelic-based treatment candidate for AUD.

Why it matters — This marks a key milestone in advancing CMND-100's clinical development for AUD, a core focus of Clearmind's pipeline.

Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results

GlobeNewsWire · 8 Sept 2026positive

Clearmind Medicine announced that Yale University's IRB has approved the initiation of patient recruitment for Parts B and C of its Phase I/II clinical trial evaluating CMND-100, following positive safety results from earlier phases. The trial targets neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder.

Why it matters — This regulatory approval enables Clearmind to advance patient recruitment for the next stages of its lead clinical trial, a key milestone in the CMND-100 development program.

Clearmind Medicine Stock Slides Friday: What's Happening?

Benzinga · 4 Sept 2026negative

Clearmind Medicine Inc. (NASDAQ:CMND) shares traded lower Friday morning as investors reacted to news that the clinical-stage biotech company is expanding beyond its core pharmaceutical focus by acquiring a majority stake in an electric vehicle charging firm.

Why it matters — CMND watchers would care because the company's move outside its drug-development focus appears to have weighed on investor sentiment, as reflected in the share decline.

FAQ

Frequently asked questions about CMND stock

How does Ticker Nerd's model rank CMND?

As at 19 Sept 2026, Clearmind Medicine, Inc. ranks 6 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).

What is the CMND stock forecast for 2030?

No analyst covering Clearmind Medicine, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CMND are extrapolating price history, which says nothing about the business.

How has CMND stock performed over the past year?

Clearmind Medicine, Inc. returned -99.8% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Clearmind Medicine, Inc. do?

Clearmind Medicine Inc. Common Shares represents equity in Clearmind Medicine Inc., a clinical-stage biotechnology company focused on developing novel psychedelic-derived therapeutics and neuroplastogen-based compounds for underserved health conditions.

What is the latest news on CMND?

The most recent item we track (TheNewswire, 17 Sept 2026): "Stickit Technologies Announces Corporate Update: Leadership Appointments, Capital Restructuring & Loan Acquisition, And Update Of Intellectual Property Portfolio". StickIt Technologies issued a corporate update outlining changes to its board of directors and executive management, recent financial transactions including loan acquisitions and private placements, and developments across its international intellectual property portfolio of proprietary cannabinoid and plant extract delivery technologies.

Company

About Clearmind Medicine, Inc.

Clearmind Medicine Inc. Common Shares represents equity in Clearmind Medicine Inc., a clinical-stage biotechnology company focused on developing novel psychedelic-derived therapeutics and neuroplastogen-based compounds for underserved health conditions. The company’s current work centers on researching and advancing treatments for alcohol use disorder and related behavioral health indications, using proprietary small-molecule drug candidates designed to target underlying neurobiological pathways. Clearmind Medicine also operates consumer-oriented and research-driven programs tied to its therapeutic platform, reflecting a broader approach that combines pharmaceutical development with adjacent product concepts. Based in Vancouver, Canada, with active research and development activities in Israel, Clearmind Medicine participates in the life sciences market through a specialized pipeline aimed at regulated medicine development. Its common shares are used by investors to gain exposure to the company’s ongoing biotech research, clinical programs, and intellectual property-driven business model.

Canada · https://www.clearmindmedicine.com